BioNTech SE (22UAy)

193.95
-3.95(-2.00%)
  • Volume:
    20,536
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    184.00 - 198.50

22UAy Overview

Prev. Close
197.9
Day's Range
184-198.5
Revenue
-
Open
198
52 wk Range
46.01-207.9
EPS
-
Volume
20,536
Market Cap
-
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
32,445
P/E Ratio
-
Beta
-
1-Year Change
296.42%
Shares Outstanding
-
Next Earnings Date
Aug 09, 2021
What is your sentiment on BioNTech SE?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE News

BioNTech SE Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuySellStrong BuyBuy
SummaryStrong BuyStrong BuyNeutralStrong BuyStrong Buy

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
2200

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More
  • COVID-19 vaccines made by AstraZeneca (NASDAQ:AZN) and the Pfizer-BioNTech alliance remain broadly effective against Delta and Kappa variants of the COVID-19 causing virus, which were first identified in India, according to a scientific study, underpinning a continued push to deliver the shots.
    0
    • 🚀🚀🚀🚀🚀🚀🚀
      0
      • June 23 (Reuters) - Rare cases of heart inflammation in adolescents and young adults is likely linked to vaccination with the Pfizer/BioNTech and Moderna COVID-19 shots, a group of doctors advising the U.S. Centers for Disease Control and Prevention (CDC) said in a presentation released on Wednesday.
        1
        • today 210-215 level possible..
          0
          • 🚀🚀🚀🚀
            1
            • FRANKFURT, June 22 (Reuters) BioNTech shareholders meeting; The statement that the virus will last for another 5-10 years should draw the attention of many! 3rd Third vaccination advantageous. Data come from the clinical study. Virus relevant for another 5 to 10 years. Seems Vaccination every yearAt the moment 14 product candidates in 16 studies.
              1
              • 🚀🚀🚀🚀🚀
                1
            • ZURICH, June 22 (Reuters) - Switzerland on Tuesday said children between 12 and 15 years old could be vaccinated against COVID-19 with the shot from Pfizer and its German partner BioNTech.
              1
              • soon above 250🚀🚀🚀
                1
                • Zacks reported; The new, highly contagious variant of COVID-19 — Delta — has fueled the risk of a third wave of infection across the globe.The spread of this highly infectious variant of COVID-19 is increasing the risk of another surge of cases worldwide.This certainly increases the demand for Pfizer-BioNTech COVID-19 vaccine and other ones.
                  1
                  • Pfizer-BioNTech has been most effective vaccine against Covid variants with proven results. Also power of Pfizer provides unrivalled, fastest global supply capability.
                    1
                    • The first patient has been treated in a Phase II cancer vaccine trial by BioNTech, evaluating its mRNA-based therapy BNT111 in combination with Libtayo (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.
                      1
                      • great news..very promising..🚀🚀
                        1
                    • These days, Delta variant spreading in UK fastly. Vaccines done in UK are mostly Astra Zenaca. The protection rate of AZ against Delta is 60% which is relatively low. The Pfizer-BioNTech vaccine is 88% effective against symptomatic COVID-19 caused by the Delta variant two weeks after the second dose.
                      1
                      • I have two pfizer shots... hyperinmunized!!!
                        0
                    • Messenger RNA vaccine technology is a DISRUPTIVE INNOVATION and Pfizer-Biontech MAKES HISTORY. Will reach 340-350 level soon.
                      1
                      • Source- Benzinga /Pharma: BioNTech SE (NASDAQ: BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine.
                        1
                        • last call for new entrants. soon 245🚀🚀🚀🚀
                          1
                          • Source: BioSpace, Jun 15, 2021, By Mark Terry: Forza BioNTech!!! The overall market for COVID-19 vaccines is projected to $67 billion in 2021, and $61 billion in 2022. As per Q1-2021 data;#1 is Pfizer-BioNTech COVID-19 vaccine. U.S. sales were $2.038 billion; global sales were $5.833 billion. #2 is Moderna COVID-19 vaccine. U.S. sales, $1.358 billion; global sales, $1.733 billion. Pfizer-BioNTech and Moderna COVID-19 vaccines account for more than 60% of the total COVID-19 market estimate in 2021 and 2022. As per lab data suggest, BioNTech is the most effective vaccine against the UK variant as well as the South African, Latin American and Delta variants.
                            1
                            • 🚀🚀🚀🚀🚀🚀🚀
                              1
                              • CBC News Canada: As per The National Advisory Committee on Immunization (NACI) in Canada announced, the people who took 1st dose of AstraZenaca, as 2nd dose they will take Pfizer-BioNTech COVID-19 Vaccine, or Moderna. Since early May, all provinces have halted the use of AstraZeneca for first doses.
                                1
                                • CBB News Canada: As per The National Advisory Committee on Immunization (NACI) in Canada announced, they stop administering the people who took 1st dose of AstraZenaca, as 2nd dose they will take Pfizer-BioNTech COVID-19 Vaccine, or Moderna. Since early May, all provinces have halted the use of AstraZeneca for first doses.
                                  1
                                  • soon 245..🚀🚀🚀
                                    1
                                    • Barron’s Investing in Tech Conference: CEO of BioNTech, Ugur Sahin said; Delta mutation continues to increase rapidly. The Delta mutation is also spreading, although 50 percent of people in the UK get their second dose of vaccine. This shows that we need to be cautious against the virus. If we are not careful, we may face a fourth wave of corona virus in certain regions. Re-vaccination, 3rd dose, should be done 6 to 9 months after two doses.
                                      1
                                      • BNTX 🚀🚀🚀
                                        1
                                    • Developing an effective vaccine, and its manufacturing and distribution is a very complicated process and BIG JOB. Look, CureVac failed and stock dropped 50% in a few hours. See the VALUE of BioNTech and appreciate it. Will see new records soon.
                                      1
                                      • BNTX 🚀🚀🚀
                                        1
                                    • You can't always go up, in fact you have to go down to go up.
                                      1
                                      • New EU contract 2021-2023 with @BioNTech_Group @Pfizer signed;Total 1.8 billion doses
                                        1
                                        • On the 8th of June I wrote "4 days ago I warned you about price drop comming. And now there it is. I think it will go down to 200or so." This price drop was inevitable
                                          2
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.